Latest filings (excl ownership)
8-K
Departure of Directors or Certain Officers
12 Mar 24
EFFECT
Notice of effectiveness
9 Feb 24
10-Q
2024 Q1
Quarterly report
8 Feb 24
8-K
Enrollment Ongoing Across Three RSV Phase 2 Studies; Anticipates Announcing Topline Data for RSVPEDs and EDP-323 Challenge Study in Q3 2024
7 Feb 24
CORRESP
Correspondence with SEC
6 Feb 24
ARS
2023 FY
Annual report to shareholders
26 Jan 24
DEFA14A
Additional proxy soliciting materials
26 Jan 24
DEF 14A
Definitive proxy
26 Jan 24
8-K
Departure of Directors or Certain Officers
26 Dec 23
UPLOAD
Letter from SEC
27 Nov 23
S-3
Shelf registration
22 Nov 23
10-K
2023 FY
Annual report
22 Nov 23
POSASR
Automatic shelf registration (post-effective amendment)
22 Nov 23
8-K
Results of Operations and Financial Condition
20 Nov 23
S-8
Registration of securities for employees
8 Aug 23
10-Q
2023 Q3
Quarterly report
8 Aug 23
8-K
Results of Operations and Financial Condition
7 Aug 23
8-K
Regulation FD Disclosure
7 Jun 23
10-Q
2023 Q2
Quarterly report
9 May 23
8-K
Strengthened Balance Sheet Through the Sale of 54.5% of Future MAVYRET®/MAVIRET® Royalties for an Upfront Payment of $200 Million
8 May 23
8-K
Non-Dilutive and Strengthens Balance Sheet
27 Apr 23
8-K
Regulation FD Disclosure
10 Mar 23
8-K
Submission of Matters to a Vote of Security Holders
7 Mar 23
10-Q
2023 Q1
Quarterly report
8 Feb 23
8-K
Results of Operations and Financial Condition
7 Feb 23
ARS
2022 FY
Annual report to shareholders
7 Feb 23
DEFA14A
Additional proxy soliciting materials
20 Jan 23
DEF 14A
Definitive proxy
20 Jan 23
10-K
2022 FY
Annual report
23 Nov 22
8-K
Results of Operations and Financial Condition
21 Nov 22
8-K
Entry into a Material Definitive Agreement
26 Aug 22
424B5
Prospectus supplement for primary offering
26 Aug 22
10-Q
2022 Q3
Quarterly report
8 Aug 22
8-K
Results of Operations and Financial Condition
8 Aug 22
8-K
Other Events
22 Jun 22
8-K
Entry into a Material Definitive Agreement
17 May 22
S-8
Registration of securities for employees
9 May 22
10-Q
2022 Q2
Quarterly report
9 May 22
8-K
Expects Topline Data From RSVP, a Phase 2b Study of EDP-938 in Adults With Community-Acquired Respiratory Syncytial Virus (RSV), This Quarter
9 May 22
8-K
Departure of Directors or Certain Officers
9 Mar 22
Latest ownership filings
4
Terry Vance
8 Mar 24
4
Lesley Russell
8 Mar 24
4
Kristine Peterson
8 Mar 24
4
Yujiro S Hata
8 Mar 24
4
MARK G FOLETTA
8 Mar 24
4
BRUCE L A CARTER
8 Mar 24
4
Nathaniel S. Gardiner
27 Feb 24
4
Brendan Luu
14 Feb 24
4
Tara Lynn Kieffer
14 Feb 24
4
Nathaniel S. Gardiner
14 Feb 24
4
Scott T. Rottinghaus
14 Feb 24
4
Yat Sun Or
14 Feb 24
4
PAUL J MELLETT
14 Feb 24
4
Jay R. Luly
14 Feb 24
SC 13G/A
ARMISTICE CAPITAL, LLC
14 Feb 24
SC 13G/A
VANGUARD GROUP INC
13 Feb 24
SC 13G/A
Farallon Capital Partners, L.P.
26 Jan 24
SC 13G/A
BlackRock Inc.
24 Jan 24
SC 13G/A
STATE STREET CORP
22 Jan 24
SC 13G
MILLENNIUM MANAGEMENT LLC
11 Jan 24
4
Terry Vance
15 Dec 23
144
Notice of proposed sale of securities
12 Dec 23
4
Brendan Luu
6 Dec 23
4
Tara Lynn Kieffer
6 Dec 23
4
Nathaniel S. Gardiner
6 Dec 23
4
Scott T. Rottinghaus
6 Dec 23
4
Yat Sun Or
6 Dec 23
4
PAUL J MELLETT
6 Dec 23
4
Jay R. Luly
6 Dec 23
4
Brendan Luu
5 Dec 23
4
Tara Lynn Kieffer
5 Dec 23
4
Nathaniel S. Gardiner
5 Dec 23
4
Yat Sun Or
5 Dec 23
4
PAUL J MELLETT
5 Dec 23
4
Jay R. Luly
5 Dec 23
4
Brendan Luu
22 Nov 23
4
Tara Lynn Kieffer
22 Nov 23
4
PAUL J MELLETT
22 Nov 23
4
Nathaniel S. Gardiner
22 Nov 23
4
Yat Sun Or
22 Nov 23